1. Phenotypic characterization of people at risk of atrial fibrillation: protocol for the FIND-AF longitudinal cohort study.
- Author
-
Wahab A, Nadarajah R, Reynolds C, Bennett S, Ambakederemo E, Harris M, Younsi T, Joseph T, Raveendra K, Smith A, Bhatty A, Lip GYH, Swoboda PP, Wu J, and Gale CP
- Subjects
- Humans, Prospective Studies, Risk Assessment, Risk Factors, Longitudinal Studies, Male, Female, Adult, Middle Aged, Electronic Health Records, Multicenter Studies as Topic, Predictive Value of Tests, Research Design, Electrocardiography, Ambulatory, Biomarkers blood, Aged, Atrial Fibrillation epidemiology, Atrial Fibrillation diagnosis, Atrial Fibrillation prevention & control, Phenotype
- Abstract
Aims: The Future Innovations in Novel Detection of Atrial Fibrillation (FIND-AF) longitudinal cohort study is a multi-centre prospective cohort study of patients identified at risk of atrial fibrillation (AF). The aim of the FIND-AF longitudinal cohort study is to provide multi-modal phenotypic characterization of these patients., Methods and Results: A total of 1955 participants identified as at risk of AF by the FIND-AF algorithm from primary care electronic health record (EHR) data, aged 30 years and above and eligible for oral anticoagulation, will be recruited between October 2023 and November 2024 to receive home-based intermittent electrocardiogram monitoring. About 500 participants without diagnosed AF will then undergo cross-sectional phenotypic characterization including physical examination, symptoms assessment, serum blood biomarkers and echocardiography, and non-stress cardiac magnetic resonance imaging. Longitudinal information about cardio-renal-metabolic-pulmonary outcomes will be ascertained from linkages to EHR data. The study is funded by the British Heart Foundation (CC/22/250026). The study has ethical approval (North West-Greater Manchester South Research Ethics Committee reference 23/NW/0180). Findings will be announced at relevant conferences and published in peer-reviewed journals in line with the funder's open-access policy., Conclusion: The FIND-AF multi-centre prospective longitudinal cohort study aims to (i) provide evidence for the impact of comorbidities on AF genesis, (ii) uncover actionable targets to prevent AF, and (iii) act as a platform for cohort randomized clinical trials that investigate enhanced detection and prevention of AF., Competing Interests: Conflict of interest: C.P.G. reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press. He has received educational and research grants from BMS, Abbott Inc., the British Heart Foundation, National Institute of Health Research, and Horizon 2020 and from the European Society of Cardiology, outside the submitted work. G.Y.H.L. is a National Institute for Health and Care Research (NIHR) senior investigator and has been a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Anthos. All other authors declare no competing interests., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF